CN113769072A - Functional product with effect of preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Functional product with effect of preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN113769072A CN113769072A CN202111092443.4A CN202111092443A CN113769072A CN 113769072 A CN113769072 A CN 113769072A CN 202111092443 A CN202111092443 A CN 202111092443A CN 113769072 A CN113769072 A CN 113769072A
- Authority
- CN
- China
- Prior art keywords
- parts
- grape seed
- functional product
- seed extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 47
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 47
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 47
- 230000000694 effects Effects 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title abstract description 23
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 56
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 56
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 56
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 229940086319 nattokinase Drugs 0.000 claims abstract description 23
- 108010073682 nattokinase Proteins 0.000 claims abstract description 23
- 108010004032 Bromelains Proteins 0.000 claims abstract description 22
- 239000004365 Protease Substances 0.000 claims abstract description 22
- 235000019835 bromelain Nutrition 0.000 claims abstract description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 20
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 20
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 20
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 20
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 20
- 239000011718 vitamin C Substances 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 15
- 229930064664 L-arginine Natural products 0.000 claims abstract description 13
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 13
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims description 83
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 57
- 239000002245 particle Substances 0.000 claims description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 39
- 229940087559 grape seed Drugs 0.000 claims description 37
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 238000011081 inoculation Methods 0.000 claims description 20
- 239000004376 Sucralose Substances 0.000 claims description 19
- 235000012239 silicon dioxide Nutrition 0.000 claims description 19
- 239000000377 silicon dioxide Substances 0.000 claims description 19
- 235000019408 sucralose Nutrition 0.000 claims description 19
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 19
- 241000228245 Aspergillus niger Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000004310 lactic acid Substances 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 9
- 235000007189 Oryza longistaminata Nutrition 0.000 claims description 8
- 240000007594 Oryza sativa Species 0.000 claims description 8
- 235000007164 Oryza sativa Nutrition 0.000 claims description 8
- 241000219095 Vitis Species 0.000 claims description 8
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 8
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 8
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- 241000235342 Saccharomycetes Species 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000009697 arginine Nutrition 0.000 claims description 7
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 241000124033 Salix Species 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 18
- 210000004204 blood vessel Anatomy 0.000 abstract description 15
- 230000002708 enhancing effect Effects 0.000 abstract description 13
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 3
- -1 lipid peroxide Chemical class 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000006806 disease prevention Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940057059 monascus purpureus Drugs 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22004—Bromelain (3.4.22.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
Abstract
The invention discloses a functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases and a preparation method thereof, wherein the functional product comprises the following raw materials in parts by weight: 15-25 parts of L-arginine, 6-14 parts of grape seed extract, 20-30 parts of bromelain, 12-18 parts of red yeast rice extract, 2-8 parts of nattokinase, 5-9 parts of vitamin C, 2-8 parts of orange powder and 6-15 parts of maltodextrin. Under the combined action of the raw materials, the functional product realizes the prevention and treatment of cardiovascular and cerebrovascular diseases in various aspects such as inhibiting the generation of lipid peroxide, decomposing cholesterol, dissolving old thrombus, enhancing the toughness and elasticity of blood vessels, enhancing the body function and the like, so that the functional product has quick and efficient prevention and treatment effects on the cardiovascular and cerebrovascular diseases.
Description
Technical Field
The invention relates to the technical field of prevention and treatment of blood and cerebral vessels, in particular to a functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases and a preparation method thereof.
Background
Cardiovascular and cerebrovascular diseases are the general names of cardiovascular and cerebrovascular diseases, and generally refer to ischemic or hemorrhagic diseases of heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension and the like; the root cause of cardiovascular and cerebrovascular diseases is that the blood vessel pathological changes caused by lipid peroxides form thrombus, so that the brain, the heart, organs and tissues of a human body are diseased.
The reasons for thrombosis mainly include: the higher the content of platelets, red white blood cells and fibrin in blood is, the more viscous the blood is, and long-term thrombus factors aggregate to generate thrombus; the exercise amount is small, the blood supply function of the heart is weak, the blood is viscous, and the like, so that the blood flow is slow, and the formation of thrombus is accelerated; the four high blood vessel wall can be rough, atherosclerosis can be caused, and the damage of the inner wall of the blood vessel is the basic condition of thrombosis.
At present, the treatment medicines for the cardiovascular and cerebrovascular diseases mainly comprise western medicines, traditional Chinese medicines and thrombolytic medicines, wherein the western medicines comprise aspirin and are mainly used for reducing the aggregation of platelets and reducing blood viscosity so as to achieve the treatment purpose; the traditional Chinese medicines comprise salvia miltiorrhiza, ginkgo and the like, and are used for promoting blood circulation to remove blood stasis, reducing the number of red blood cells and regulating blood fat; thrombolytic drugs include streptokinase, urokinase, and the like, and are generally used in rescue; however, western medicines generally have certain side effects and cause certain damage to the body; the traditional Chinese medicine has the problems of single function, incapability of dissolving old thrombus and slow effect; in addition, cardiovascular and cerebrovascular diseases can also be treated by bypass surgery; however, the existing surgical treatment has high risk and high cost and needs timing detection.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a functional product with the efficacy of preventing and treating cardiovascular and cerebrovascular diseases and a preparation method thereof, and the functional product has the efficacy of dissolving old thrombus, reducing blood viscosity, increasing blood flow and removing free radicals, thereby achieving the prevention and treatment of the cardiovascular and cerebrovascular diseases.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
the invention provides a functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following raw materials in parts by weight:
15-25 parts of L-arginine, 6-14 parts of grape seed extract, 20-30 parts of bromelain, 12-18 parts of red yeast rice extract, 2-8 parts of nattokinase, 5-9 parts of vitamin C, 2-8 parts of orange powder and 6-15 parts of maltodextrin.
The invention adopts the following raw materials:
l-arginine is a very strong vasodilating substance and plays an important role in maintaining the constancy of vascular tone and regulating the stability of blood pressure; l-arginine is a precursor of NO production, and supplement of L-arginine promotes NO production, and can promote vasodilatation and angiogenesis; the blood vessel is expanded to promote blood to flow to various parts of human body, and the effects of keeping blood vessel clean, maintaining normal blood pressure and preventing heart disease are achieved.
The grape seed extract is rich in polyphenols such as procyanidin, catechin, epicatechin, gallic acid, epicatechin gallate, etc.; the product has excellent oxidation resistance, can effectively remove free radicals, enhance myocardial blood supply, supplement nutrient elements and strengthen the organism; in addition, the grape seed extract can also play a certain role in protecting blood vessels, enhancing the elasticity of the blood vessels and playing a good role in preventing and treating cardiovascular and cerebrovascular diseases.
Bromelain can catalyze the breakage of peptide bonds in proteins, so that proteins, peptides, lipids, amides and other substances are decomposed, and the bromelain has the effects of resisting inflammation and eliminating edema; simultaneously, the composition can inhibit heart attack and apoplexy caused by platelet aggregation, relieve angina pectoris symptoms, relieve arterial contraction, accelerate decomposition of fibrinogen, and recover blood circulation.
The red rice extract contains monascus pigment, lovastatin, ergosterol, enzyme active substance and gamma-aminobutyric acid; it has effects of promoting blood circulation for removing blood stasis, reducing blood lipid and total cholesterol, directly inhibiting HNG-coA reductase, blocking cholesterol synthesis, reducing blood concentration and viscosity, and promoting blood flow.
Nattokinase is a serine protease produced by bacillus subtilis in the fermentation process of natto; it has effects in dissolving thrombus, reducing blood viscosity, improving blood circulation, softening and increasing blood vessel elasticity; the nattokinase can activate and enhance the thrombolysis capacity of a human body while directly dissolving the formed thrombus, thereby playing a role of durable and stable thrombolysis, and the nattokinase only dissolves the main substance fibrin of the thrombus, does not hydrolyze plasma fibrinogen, and does not cause the risk of bleeding.
The vitamin C has strong reducibility, is easily oxidized into dehydrovitamin C, and has the effects of resisting oxidation and free radicals.
The willow orange powder contains various nutrient elements, particularly abundant vitamins and/or carotene and the like, and after being absorbed by organisms, various nutrient substances can activate cell activity, improve toughness and elasticity of blood vessels, and contribute to softening the blood vessels, purifying the blood and promoting blood circulation, so that the function of preventing arteriosclerosis is achieved.
The maltodextrin contains certain vitamins and trace elements, particularly calcium, iron and other trace elements and mineral substances beneficial to a human body, and can promote normal metabolism and metabolism of the human body; in addition, the emulsion has good emulsification and thickening effects, can protect the components of the raw materials to a certain extent, and effectively promotes the absorption of the raw materials by organisms.
The functional product realizes the prevention and treatment of cardiovascular and cerebrovascular diseases from multiple aspects under the combined action of all raw materials, and specifically, on the first aspect, the inhibition and inhibition means the reduction of platelet aggregation and the inhibition of the generation of lipid peroxide, so that the purpose of blood viscosity is achieved; in the second aspect, the decomposition means that the cholesterol is decomposed, old thrombus is dissolved, and the effects of reducing blood fat and promoting blood circulation are achieved; in the third aspect, activation refers to activation of cell dynamics and restoration of the elasticity of the inner wall of the blood vessel, so as to achieve the effect of enhancing the toughness and elasticity of the blood vessel; in the fourth aspect, enhancing means scavenging free radicals, enhancing oxidation resistance, enhancing myocardial blood supply, supplementing nutrient elements and enhancing body functions; in addition, the raw materials are reasonably proportioned, so that the functional product has quick and efficient prevention and treatment effects on cardiovascular and cerebrovascular diseases.
In order to improve the mouthfeel and stability of the functional product, the raw materials of the invention preferably further comprise:
1-3 parts of sucralose, 0.2-0.6 part of citric acid and 0.2-0.6 part of silicon dioxide.
In the invention, the sucralose, the citric acid and the silicon dioxide are added as inactive ingredients, so that the mouthfeel of functional products and the environment of each raw material can be improved, and the active ingredients of each raw material can be better included.
Preferably, the functional product comprises the following raw materials in parts by weight:
18-22 parts of L-arginine, 8-12 parts of grape seed extract, 24-28 parts of bromelain, 14-16 parts of red yeast rice extract, 4-6 parts of nattokinase, 6-7 parts of vitamin C, 4-6 parts of orange powder, 8-12 parts of maltodextrin, 2-3 parts of sucralose, 0.4-0.6 part of citric acid and 0.4-0.6 part of silicon dioxide.
Further preferably, the functional product comprises the following raw materials in parts by weight:
20 parts of L-arginine, 10 parts of grape seed extract, 25 parts of bromelain, 15 parts of red yeast rice extract, 5 parts of nattokinase, 7 parts of vitamin C, 5 parts of willow orange powder, 10 parts of maltodextrin, 2 parts of sucralose, 0.5 part of citric acid and 0.5 part of silicon dioxide.
In the invention, different raw material proportions directly influence the content of effective components in the functional product, thereby causing the change of the overall efficacy of the functional product.
The grape seed extract is not strictly limited in the present invention, and for example, a grape seed extract conventional in the art may be selected; preferably, the grape seed extract is prepared by the following method:
(a) soaking and crushing grape seeds to obtain grape seed particles;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into the grape seed particles and fermenting to obtain a fermentation product;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
The preparation method can effectively decompose macromolecular substances in the grape seeds and promote the separation of effective components by performing fermentation treatment through specific strains, so that the grape seed extract has more excellent effect.
Further, the soaking time is 2-4 h; the particle size of the grape seed particles is not more than 2 mm.
Further, the inoculation amount of the aspergillus niger is 1-3% of the mass of the grape seed particles; the inoculation amount of the microzyme is 2 to 6 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.1-0.5% of the mass of the grape seed particles.
Further, the fermentation temperature is 27-35 ℃, and the fermentation time is 4-6 days.
The second aspect of the present invention provides a method for preparing the functional product, wherein the method comprises the following steps:
(1) pulverizing grape seed extract to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
Preferably, the grape seed extract powder has a mesh size of not less than 100 mesh.
Compared with the prior art, the invention has the beneficial effects that at least:
the functional product realizes prevention and treatment of cardiovascular and cerebrovascular diseases from multiple aspects under the combined action of all raw materials, and specifically, on the first aspect, inhibition and inhibition mean reduction of platelet aggregation and inhibition of lipid peroxide generation, so that the purpose of blood viscosity is achieved; in the second aspect, the decomposition means that the cholesterol is decomposed, old thrombus is dissolved, and the effects of reducing blood fat and promoting blood circulation are achieved; in the third aspect, activation refers to activation of cell dynamics and restoration of the elasticity of the inner wall of the blood vessel, so as to achieve the effect of enhancing the toughness and elasticity of the blood vessel; in the fourth aspect, enhancing means scavenging free radicals, enhancing oxidation resistance, enhancing myocardial blood supply, supplementing nutrient elements and enhancing body functions; in addition, the raw materials are reasonably proportioned, so that the functional product has quick and efficient prevention and treatment effects on cardiovascular and cerebrovascular diseases.
Detailed Description
The following describes embodiments of the present invention in detail with reference to the following embodiments. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
Functional product with cardiovascular and cerebrovascular disease prevention and treatment effects
The functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following raw materials in parts by weight:
25 parts of L-arginine, 6 parts of grape seed extract, 30 parts of bromelain, 12 parts of red yeast rice extract, 8 parts of nattokinase, 9 parts of vitamin C, 2 parts of willow orange powder, 6 parts of maltodextrin, 3 parts of sucralose, 0.6 part of citric acid and 0.2 part of silicon dioxide,
wherein, the grape seed extract is prepared by the following method:
(a) soaking grape seeds in water for 4h, draining, and crushing to obtain grape seed particles with particle size not greater than 2 mm;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into grape seed particles, fermenting at 27 ℃ for 6 days, and turning over materials at intervals of 24 hours to obtain a fermentation product, wherein the inoculation amount of the aspergillus niger is 1% of the mass of the grape seed particles; the inoculation amount of the microzyme is 6 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.1 percent of the mass of the grape seed particles;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
Second, preparation method
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following steps:
(1) crushing the grape seed extract, and sieving with a 100-mesh sieve to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
Example 2
Functional product with cardiovascular and cerebrovascular disease prevention and treatment effects
The functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following raw materials in parts by weight:
15 parts of L-arginine, 14 parts of grape seed extract, 20 parts of bromelain, 18 parts of red yeast extract, 2 parts of nattokinase, 5 parts of vitamin C, 8 parts of willow orange powder, 15 parts of maltodextrin, 1 part of sucralose, 0.2 part of citric acid and 0.6 part of silicon dioxide,
wherein, the grape seed extract is prepared by the following method:
(a) soaking grape seeds in water for 2h, draining, and crushing to obtain grape seed particles with particle size not greater than 2 mm;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into grape seed particles, fermenting for 4 days at 35 ℃, and turning over materials at intervals of 24 hours to obtain a fermentation product, wherein the inoculation amount of the aspergillus niger is 3% of the mass of the grape seed particles; the inoculation amount of the microzyme is 2 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.5 percent of the mass of the grape seed particles;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
Second, preparation method
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following steps:
(1) crushing the grape seed extract, and sieving with a 100-mesh sieve to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
Example 3
Functional product with cardiovascular and cerebrovascular disease prevention and treatment effects
The functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following raw materials in parts by weight:
22 parts of L-arginine, 8 parts of grape seed extract, 24 parts of bromelain, 16 parts of red yeast extract, 6 parts of nattokinase, 6 parts of vitamin C, 6 parts of orange powder, 8 parts of maltodextrin, 3 parts of sucralose, 0.4 part of citric acid and 0.6 part of silicon dioxide,
wherein, the grape seed extract is prepared by the following method:
(a) soaking grape seeds in water for 3h, draining, and crushing to obtain grape seed particles with particle size not greater than 2 mm;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into the grape seed particles, fermenting for 5 days at 32 ℃, and turning over materials at intervals of 24 hours to obtain a fermentation product, wherein the inoculation amount of the aspergillus niger is 2% of the mass of the grape seed particles; the inoculation amount of the microzyme is 4 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.2 percent of the mass of the grape seed particles;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
Second, preparation method
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following steps:
(1) crushing the grape seed extract, and sieving with a 100-mesh sieve to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
Example 4
Functional product with cardiovascular and cerebrovascular disease prevention and treatment effects
The functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following raw materials in parts by weight:
18 parts of L-arginine, 12 parts of grape seed extract, 28 parts of bromelain, 14 parts of red yeast extract, 4 parts of nattokinase, 7 parts of vitamin C, 4 parts of orange powder, 12 parts of maltodextrin, 2 parts of sucralose, 0.6 part of citric acid and 0.4 part of silicon dioxide,
wherein, the grape seed extract is prepared by the following method:
(a) soaking grape seeds in water for 3h, draining, and crushing to obtain grape seed particles with particle size not greater than 2 mm;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into the grape seed particles, fermenting for 5 days at 32 ℃, and turning over materials at intervals of 24 hours to obtain a fermentation product, wherein the inoculation amount of the aspergillus niger is 2% of the mass of the grape seed particles; the inoculation amount of the microzyme is 4 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.2 percent of the mass of the grape seed particles;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
Second, preparation method
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following steps:
(1) crushing the grape seed extract, and sieving with a 100-mesh sieve to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
Example 5
Functional product with cardiovascular and cerebrovascular disease prevention and treatment effects
The functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following raw materials in parts by weight:
20 parts of L-arginine, 10 parts of grape seed extract, 25 parts of bromelain, 15 parts of red yeast extract, 5 parts of nattokinase, 7 parts of vitamin C, 5 parts of willow orange powder, 10 parts of maltodextrin, 2 parts of sucralose, 0.5 part of citric acid and 0.5 part of silicon dioxide,
wherein, the grape seed extract is prepared by the following method:
(a) soaking grape seeds in water for 3h, draining, and crushing to obtain grape seed particles with particle size not greater than 2 mm;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into the grape seed particles, fermenting for 5 days at 32 ℃, and turning over materials at intervals of 24 hours to obtain a fermentation product, wherein the inoculation amount of the aspergillus niger is 2% of the mass of the grape seed particles; the inoculation amount of the microzyme is 4 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.2 percent of the mass of the grape seed particles;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
Second, preparation method
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases comprises the following steps:
(1) crushing the grape seed extract, and sieving with a 100-mesh sieve to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
Comparative example 1
The comparative example is a functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases, and the functional product is basically the same as the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases in example 5, and is different only in that the red yeast extract is replaced by the same amount of grape seed extract.
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases is the same as the preparation method in the embodiment 5.
Comparative example 2
The comparative example is a functional product with the efficacy of preventing and treating cardiovascular and cerebrovascular diseases, and the functional product is basically the same as the functional product with the efficacy of preventing and treating cardiovascular and cerebrovascular diseases in example 5, and is different from the functional product with the efficacy of preventing and treating cardiovascular and cerebrovascular diseases only in that bromelain is replaced by the same amount of nattokinase.
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases is the same as the preparation method in the embodiment 5.
Comparative example 3
The comparative example is a functional product with the efficacy of preventing and treating cardiovascular and cerebrovascular diseases, and the functional product is basically the same as the functional product with the efficacy of preventing and treating cardiovascular and cerebrovascular diseases in example 5, and is different only in that yeast is replaced by the same amount of aspergillus niger in the preparation process of the grape seed extract.
The preparation method of the functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases is the same as the preparation method in the embodiment 5.
Examples of the experiments
Respectively obtaining the functional products with the effect of preventing and treating cardiovascular and cerebrovascular diseases in the embodiments 3-5 and the comparative examples 1-3;
1. artificial thrombolysis test
Taking non-anticoagulated blood, quickly injecting the non-anticoagulated blood into a silica gel tube with the diameter of 5mm, and injecting 1ml into each tube to form artificial thrombus;
respectively taking 5g of the functional products with the effect of preventing and treating cardiovascular and cerebrovascular diseases of the embodiments 3-5 and the comparative examples 1-3; respectively dissolving in 10ml of deionized water at 37 ℃ to obtain functional product solutions;
placing the artificial thrombus in the functional product solution and deionized water (as blank control) at 37 ℃; respectively recording the complete dissolution time of the thrombus, repeating the time for 3 times, and calculating the average time, wherein the calculation result is shown in table 1;
TABLE 1
| Group of | Time (min) |
| Example 3 | 85.2 |
| Example 4 | 79.1 |
| Example 5 | 68.7 |
| Comparative example 1 | 126.3 |
| Comparative example 2 | 94.4 |
| Comparative example 3 | 73.8 |
| Blank control | 173.2 |
As can be seen from Table 1:
compared with a blank control, the functional products of the embodiment and the comparative example can promote the dissolution of thrombus; in the examples of the present invention, the selection of each raw material provides a more excellent thrombolytic effect than in examples 5 and comparative examples 1 to 2.
2. EXAMPLE 5 study of functional products for reducing blood lipid and total cholesterol
Three volunteers with high triglyceride or total cholesterol are selected, and each volunteer takes the functional product of the embodiment 5 of the invention by taking with warm water three times a day, one bag each time, and 3g each bag;
the administration was started at 12/7 of 2020, wherein the content of triglyceride and total cholesterol in blood of each volunteer was measured at 19/12 and 3/1/2021, and the measurement results are shown in Table 2:
TABLE 2
As can be seen from Table 2:
the functional product prepared by the embodiment of the invention can effectively reduce triglyceride and total cholesterol in blood.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (10)
1. A functional product with the effect of preventing and treating cardiovascular and cerebrovascular diseases is characterized by comprising the following raw materials in parts by weight:
15-25 parts of L-arginine, 6-14 parts of grape seed extract, 20-30 parts of bromelain, 12-18 parts of red yeast rice extract, 2-8 parts of nattokinase, 5-9 parts of vitamin C, 2-8 parts of orange powder and 6-15 parts of maltodextrin.
2. The functional product according to claim 1, wherein the raw material further comprises:
1-3 parts of sucralose, 0.2-0.6 part of citric acid and 0.2-0.6 part of silicon dioxide.
3. The functional product according to claim 2, characterized by comprising the following raw materials in parts by weight:
18-22 parts of L-arginine, 8-12 parts of grape seed extract, 24-28 parts of bromelain, 14-16 parts of red yeast rice extract, 4-6 parts of nattokinase, 6-7 parts of vitamin C, 4-6 parts of orange powder, 8-12 parts of maltodextrin, 2-3 parts of sucralose, 0.4-0.6 part of citric acid and 0.4-0.6 part of silicon dioxide.
4. The functional product according to claim 3, characterized by comprising the following raw materials in parts by weight:
20 parts of L-arginine, 10 parts of grape seed extract, 25 parts of bromelain, 15 parts of red yeast rice extract, 5 parts of nattokinase, 7 parts of vitamin C, 5 parts of willow orange powder, 10 parts of maltodextrin, 2 parts of sucralose, 0.5 part of citric acid and 0.5 part of silicon dioxide.
5. The functional product according to claim 1, wherein the grape seed extract is prepared by the following method:
(a) soaking and crushing grape seeds to obtain grape seed particles;
(b) inoculating aspergillus niger, saccharomycetes and lactic acid bacteria into the grape seed particles and fermenting to obtain a fermentation product;
(c) adding water into the fermentation product, stirring, filtering, and collecting filtrate;
(d) concentrating the filtrate, and freeze drying to obtain grape seed extract.
6. The functional product according to claim 5, wherein the soaking time is 2 to 4 hours; the particle size of the grape seed particles is not more than 2 mm.
7. The functional product according to claim 5, wherein the aspergillus niger is inoculated in an amount of 1-3% of the mass of the grape seed particles; the inoculation amount of the microzyme is 2 to 6 percent of the mass of the grape seed particles; the inoculation amount of the lactic acid bacteria is 0.1-0.5% of the mass of the grape seed particles.
8. The functional product according to claim 5, wherein the fermentation temperature is 27 to 35 ℃ and the fermentation time is 4 to 6 days.
9. The method for preparing a functional product according to any one of claims 1 to 8, comprising the steps of:
(1) pulverizing grape seed extract to obtain grape seed extract powder;
(2) mixing grape seed extract powder, sucralose, citric acid, silicon dioxide, red rice extract, orange powder and maltodextrin uniformly to obtain a mixture;
(3) adding arginine, bromelain, nattokinase and vitamin C into the mixture, uniformly mixing, and bagging to obtain a bagged functional product.
10. The method of claim 9, wherein the grape seed extract powder has a mesh size of no less than 100 mesh.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111092443.4A CN113769072A (en) | 2021-09-17 | 2021-09-17 | Functional product with effect of preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111092443.4A CN113769072A (en) | 2021-09-17 | 2021-09-17 | Functional product with effect of preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113769072A true CN113769072A (en) | 2021-12-10 |
Family
ID=78851682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111092443.4A Withdrawn CN113769072A (en) | 2021-09-17 | 2021-09-17 | Functional product with effect of preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113769072A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114246917A (en) * | 2022-02-28 | 2022-03-29 | 深圳德荫堂生物科技有限公司 | Biological medicament for relieving cardiovascular and cerebrovascular diseases and production method thereof |
-
2021
- 2021-09-17 CN CN202111092443.4A patent/CN113769072A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114246917A (en) * | 2022-02-28 | 2022-03-29 | 深圳德荫堂生物科技有限公司 | Biological medicament for relieving cardiovascular and cerebrovascular diseases and production method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105053360A (en) | Functional compound enzyme tea and preparation method and use method thereof | |
| KR101497050B1 (en) | A manufacturing method of functional fermented food | |
| CN101496581B (en) | Health-care food for adjusting blood fat | |
| KR20130085782A (en) | Hair product composition for promoting growth of hair and method of manufacturing for the same | |
| KR20220013451A (en) | Fermented Noni Vinegar Comprising Lactic Acid Bacteria Fermented Noni and Coconut Sugar and Method for Preparing Lactic Acid Bacteria Fermented Noni | |
| CN109662222A (en) | Plant beverage and preparation method thereof with cell repair and promotion cell viability | |
| CN113769072A (en) | Functional product with effect of preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107692212A (en) | A kind of red pears composite enzyme of pseudo-ginseng and preparation method thereof | |
| CN103301321B (en) | Thrombolytic active polysaccharide mixture preparation technology | |
| CN105707876B (en) | It is a kind of that there is the dietary composition and its preparation method and application stablized and dissolve patch | |
| CN110200179A (en) | A kind of Morinda Citrifolia juice and preparation method thereof that is anti-oxidant, improving immunity | |
| CN106309629A (en) | Herbal essence extract and and preparing method thereof | |
| CN111480830A (en) | Enzyme liquid, application and preparation method thereof and anti-aging product | |
| KR20100102890A (en) | Process of manufacture of ability drink that use medicinal plant extraction liquid | |
| CN109645494A (en) | Improve function of human body and prevents the composition and preparation method of cardiovascular and cerebrovascular disease | |
| CN109645295A (en) | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health | |
| KR101960571B1 (en) | Method for preparing apricot extract, the apricot extract prepared therefrom, and skin care or cosmetic composition comprising the apricot extract | |
| CN108265011A (en) | Mycelium liquid fermentation medium composition of a kind of rich-selenium Agaricus blazei and preparation method thereof and fermentation process | |
| CN107736542A (en) | A kind of compound lozenge of blueberry and preparation method thereof | |
| KR101227922B1 (en) | Papaya puree and the use of the same | |
| KR20200129009A (en) | Hair regeneration and hair growth using phytosphin Promoting cosmetics | |
| KR102126132B1 (en) | Manufacturing method of ginseng-brown rice vinegar | |
| CN111374244A (en) | Sea-buckthorn protein compound beverage and preparation process thereof | |
| CN106215176A (en) | A kind of efficiently antiinflammatory multienzyme compositions | |
| JP3282032B2 (en) | Active oxygen suppression composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211210 |